ZAYED-SUSTAINABILITY
7.4.2021 14:31:09 CEST | Business Wire | Press release
With one month to go until the 6th of May submissions deadline, the Zayed Sustainability Prize, the UAE’s pioneering global award for rewarding impact, innovation, and inspiration, has today issued a final call to small-to-medium sized enterprises, non-profit organisations and high schools, around the world, to submit their entries for the 2022 edition.
Inspired by the sustainable development and humanitarian legacy of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, the Prize is now in its 14th submissions cycle after officially opening on 18th November 2020. The Prize has since recognised 86 winners whose solutions or school projects have, directly and indirectly, positively transformed the lives of more than 352 million people, worldwide.
Small-to-medium sized enterprises and non-profit organisations must enter an existing sustainability solution in one of the Health, Food, Energy, or Water categories, and demonstrate results across three core criteria: impact, innovation, and inspiration. The Global High Schools category invites student-led projects or proposals, based on one or more of the four sustainability sectors, and provides funding to help develop or enhance their school or local community.
Commenting on this year’s submissions process, H.E Dr. Sultan bin Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Director General of the Zayed Sustainability Prize said: “The Zayed Sustainability Prize focuses on contributing to the vision of the UAE’s wise leadership in terms of encouraging and driving innovation to develop practical solutions that enhance the quality of life for communities throughout the world. The Prize also announced that the 2022 cycle would be placing notable emphasis on innovation as one of the key drivers for COVID-19 response and recovery, creating synergies between vital sustainable solutions and their ability to play a role in empowering communities, while alleviating the socio-economic implications of the pandemic.”
“As the world unites around progressive climate action in the run up to COP26, sustainable solutions are growing in prominence, as they reinforce the commitment and responsibility of current generations towards the future while paving the way for greater economic opportunities. For its part, the Prize will continue to showcase and recognise the sustainable innovations that effectively tackle climate change action and beyond.”
The Prize’s US$3 million annual fund rewards winners US$600,000 in each category; the Global High Schools category is split into six world region winners, with each school able to claim up to US$100,000 to start or further expand their project. The six world regions of the Global High Schools category are The Americas, Sub-Saharan Africa, Middle East & North Africa, Europe & Central Asia, South Asia, and East Asia & Pacific.
Winners will be announced in 2022 during an Awards Ceremony as part of the Abu Dhabi Sustainability Week (ADSW). More details will be shared in the coming months.
To apply today, visit www.ZayedSustainabilityPrize.com
About Zayed Sustainability Prize
Established by the UAE leadership, in 2008, to honour the legacy of the founding father, the late Sheikh Zayed bin Sultan Al Nahyan, the Zayed Sustainability Prize is the UAE’s pioneering global award for recognising sustainability and humanitarian solutions around the world.
The Zayed Sustainability Prize acknowledges and rewards global pioneers and innovators who are committed to accelerating impactful sustainable solutions.
For over a decade, the Prize has awarded 86 winners. Collectively, they have directly and indirectly, positively impacted the lives of over 335 million people around the world. The Zayed Sustainability Prize categories are: Health, Food, Energy, Water and Global High Schools.
For more information, please visit www.ZayedSustainabilityPrize.com or go to our social media platforms on, Twitter , Facebook , Instagram , YouTube .
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005593/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom